USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: THERALOGICS, INC.
City: Durham
State: NC
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $1,137,540.00 4
STTR Phase II $2,281,812.00 2

Award List:

Inhibition of IkK to treat lethal Graft-vs.-Host Disease

Award Year / Program / Phase: 2008 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $885,556.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the problems associated with graft-versus-host disease (GV HD) have greatly limited the use of… More

NF-kB Inhibition of Lung Ischemia Repurfusion Injury

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
Principal Investigator: Patrick M. Flood
Award Amount: $255,627.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ transplantation, because IRI is the major cause of primar y graft failure and organ dysfunction after… More

Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: University Of Pennsylvania
Principal Investigator: Patrick M. Flood – 919-425-3586
Award Amount: $420,475.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The NF-?B family of transcription factors plays a central role in the regulation of lymphocyte proliferation, differentiation and survival. Aberrant constitutive activation of NF-?B has been identified in many differentaggressive lymphoid malignancies in humans… More

Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
Principal Investigator: Scott E. Plevy – 412-648-9573
Award Amount: $1,396,256.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs still exist. Activation of NF??B transcription factors are central events in the initiation and… More